2025
- Moser LM, Heim C, Koschade SE, Wendel P, Bozkurt S, Harenkamp S, Kreyenberg H, Merker M, Münch C, Gradhand E, Vogler M, Ullrich E, Bönig H, Klusmann JH, Bader P, Wels WS, Rettinger E.
CAR-CIK vs. CAR-T: benchmarking novel cytokine-induced killer cells as solid tumor immunotherapy in ErbB2+ rhabdomyosarcoma.Front Immunol. 2025 Feb 3;16:1485817. doi: 10.3389/fimmu.2025.1485817
2024
- Bexte T, Albinger N, Al Ajami A, Wendel P, Buchinger L, Gessner A, Alzubi J, Särchen V, Vogler M, Rasheed HM, Jung BA, Wolf S, Bhayadia R, Oellerich T, Klusmann JH, Penack O, Möker N, Cathomen T, Rieger MA, Imkeller K, Ullrich E.
CRISPR/Cas9 editing of NKG2A improves the efficacy of primary CD33-directed chimeric antigen receptor natural killer cells.Nat Commun. 2024 Sep 30;15(1):8439. - Yildirim N, Sarojam L, Smith VM, Pieper NM, Anders M, Jackson RA, Fuhrmann DC, Särchen V, Brücher D, Weigert A, Dyer MJS, Vogler M.
Identification of a novel form of caspase-independent cell death triggered by BH3-mimetics in diffuse large B-cell lymphoma cell lines.
Cell Death Dis. 2024 Apr 15;15(4):266.
2022
- Ullrich E, Vogler M, von Metzler I.
Mitochondrial apoptosis: facilitator of NK cell-mediated immunotherapy. (Research Highlight)
Signal Transduct Target Ther. 2022. 7(1):291 - Särchen V, Shanmugalingam S, Kehr S, Reindl LM , Greze V, Wiedemann S, Boedicker C, Jacob M, Bankov K, Becker N, Theilen T, Gretser S, Gradhand E , Kummerow C, Ullrich E, Vogler M.
Pediatric multicellular tumor spheroid models illustrate a therapeutic potential by combining BH3 mimetics with Natural Killer (NK) cell-based immunotherapy.
Cell Death Disc. 2022. 8 (1):11. - Vogler M, Shanmugalingam S, Särchen V, Reindl LM, Grèze V, Buchinger L, Kühn M, Ullrich E. Unleashing the power of NK cells in anticancer immunotherapy.
J Mol Med (Berl). 2022. 100 (3) 337-349
2020
- Bolomsky A, Vogler M, Köse MC, Heckman CA, Ehx G, Ludwig H, Caers J.
MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents (Review)
J Hematol Oncol. 2020.13(1):173 - Vervloessem T, Sasi B, Xerxa E, Karamanou S, Kale J, La Rovere R, Chakraborty S, Sneyers F, Vogler M, Economou A, Laurenti L, Andrews D, Efremov D, Bultynck G.
BDA-366, a putative Bcl-2 BH4 domain antagonist, induces apoptosis independently of Bcl-2 in a variety of cancer cell models
Cell Death and Dis. 2020. 11(9):769 - Kerkhofs M, Vervloessem T, Stopa KB, Smith VM, Vogler M, Bultynck G.
DLBCL Cells with Acquired Resistance to Venetoclax Are Not Sensitized to BIRD-2 But Can Be Resensitized to Venetoclax through Bcl-XL Inhibition
Biomolecules. 2020. 10(7):1081. - Smith VM, Dietz A, Henz K, Bruecher D, Jackson R, Kowald L, van Wijk SJL, Jayne S, Macip S, Fulda S, Dyer MJS, Vogler M.
Specific interactions of BCL-2 family proteins mediate sensitivity to BH3-mimetics in diffuse large B-cell lymphoma.
Haematologica. 2020. 105(8):2150. - Dietz A, Dalda N, Zielke S, Dittmann J, Wijk S, Vogler M, Fulda S (shared senior authors)
Proteasome inhibitors and Smac mimetics cooperate to induce cell death in Diffuse Large B-cell Lymphoma by stabilizing NOXA and triggering mitochondrial apoptosis
Int J Cancer. 2020. 147(5):1485. - Bierbrauer A, Jacob M, Fulda S, Vogler M. (shared senior authors)
A direct comparison of selective BH3-mimetics reveals BCL-XL, BCL-2 and MCL-1 as promising therapeutic targets in neuroblastoma
Br J Cancer 2020. 122(10):1544. - Kehr S, Haydn T, Bierbrauer A, Irmer B, Fulda S, Vogler M. (shared senior authors)
Targeting BCL-2 proteins in pediatric cancer: Dual inhibition of BCL-XL and MCL-1 leads to rapid induction of intrinsic apoptosis
Cancer Letters. 2020. 482:19. - Dittmann J, Haydn T, Ward G, Metzger P, Boerries M, Vogler M, Fulda S.
Next-generation hypomethylating agent SGI-110 primes acute myeloid leukemia cells to IAP antagonist by activating extrinsic and intrinsic apoptosis pathways
Cell Death and Differ. 2020. 27(6):1878.
2019
- Ewald L, Dittmann J, Fulda S, Vogler M. (shared senior authors)
Side-by-side comparison of BH3-mimetics identifies MCL-1 as a key therapeutic target in AML
Cell Death and Dis. 2019. 10(12):917. - Henz K, Al-Zebeeby A, Basoglu M, Fulda S, Cohen GM, Varadarajan S, Vogler M.
Selective BH3-mimetics targeting BCL-2, BCL-XL or MCL-1 induce severe mitochondrial perturbations
Biol Chem. 2019. 400(2):181. - Hugle M, Czaplinski S, Habermann K, Vogler M, Fulda S.
Identification of Smac mimetics as novel substrates for p-glycoprotein
Cancer Lett. 2019. 126:440. - Al-Zebeeby A, Vogler M, Milani M, Richards C, Alotibi A, Greaves G, Dyer MJS, Cohen GM, Varadarajan S.
Targeting intermediary metabolism enhances the efficacy of BH3 mimetic therapy in haematological malignancies
Haematologica. 2019.104(5):1016
2018
- Heinicke U, Haydn T, Kehr S, Fulda S, Vogler M. (shared senior authors)
BCL-2 selective inhibitor ABT-199 primes rhabdomyosarcoma cells to histone deacetylase inhibitor-induced apoptosis
Oncogene. 2018. 37(39):5325 - Enßle JC, Boedicker C, Wanior M, Vogler M, Knapp S, Fulda S.
Co-targeting of BET proteins and HDACs as a novel approach to trigger apoptosis in rhabdomyosarcoma cells
Cancer Lett. 2018. 428:160. - Casara P, Davidson J, Claperon A, Le Toumelin-Braizat G, Vogler M, Bruno A, Chanrion M, Lysiak-Auvity G, Le Diguarher T, Starck J, Chen I, Whitehead N, Graham C, Matassova N, Dokurno P, Pedder C, Wang Y, Qiu S, Girard A, Schneider E, Gravé F, Studeny A, Guasconi G, Rocchetti F, Maïga S, Henlin J, Colland F, Kraus-Berthier L, Le Gouill S, Dyer MJS, Hubbard R, Wood M, Amiot M, Cohen GM, Hickman JA, Morris E, Murray J, Geneste O.
S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth
Oncotarget. 2018. 9:20075. - Kozaki R, Vogler M, Walter HS, Jayne S, Dinsdale D, Siebert R, Dyer MJS, Yoshizawa T.
Responses to the Selective Bruton’s Tyrosine Kinase (BTK) Inhibitor Tirabrutinib (ONO/GS-4059) in Diffuse Large B-cell Lymphoma Cell Lines.
Cancers (Basel). 2018. 10(4). pii: E127. - Dolgikh N, Hugle M, Vogler M, Fulda S.
NRAS-mutated rhabdomyosarcoma cells are vulnerable to mitochondrial apoptosis induced by coinhibition of MEK and PI3Kα
Cancer Res. 2018. 78(8):2000.
2017
- Faqar-Uz-Zaman SF, Heinicke U, Meister M, Vogler M, Fulda S.
BCL-xL-selective BH3 mimetic sensitizes rhabdomyosarcoma cells to chemotherapeutics by activation of the mitochondrial pathway of apoptosis
Cancer Lett. 2017. 412:131. - Vogler M, Walter HS, Dyer MJS.
Targeting anti-apoptotic BCL2 family proteins in haematological malignancies – from pathogenesis to treatment (Review)
Br J Haematol. 2017. 178(3):364.